CATT研究结果支持全球继续使用玻璃体腔入路的给药途径使用倍伐单抗作为对雷珠单抗的一种廉价选择。
The CATT data support the continued global use of intravitreal bevacizumab as an effective. low-cost alternative to ranibizumab, particularly for patients paying all costs out of pocket.
例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
伐地那非是一种强效、高选择性的5型磷酸二酯酶(PDE5)抑制剂，对PDE5的抑制作用约为西地那非的10倍。
Vardenafil is a potent and highly selective phosphodiesterase type 5 (PDE5) inhibitor with a potency about 10-fold higher than sildenafil.
应用推荐